Novel Technologies for Respiratory Virus Identification

NCT ID: NCT05661032

Last Updated: 2025-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-18

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Current virus detection methods often take significant time or can be limited in sensitivity, specificity or cost. There is therefore a need for diagnostic methods that are simple to use, sensitive, rapid and inexpensive.

This is a proof of concept study to determine whether the Pictura Bio system (a new a rapid pathogen identification technology) is able to detect and differentiate different viruses from nasopharyngeal swabs/aspirate specimens. The data collected will be used to "train" the algorithms to be able to accurately identify respiratory viruses. The accuracy with which the algorithms estimate the test dataset will be monitored at regular intervals during the training dataset collection period. The Pictura Bio system is still under development, which means that it is still "learning". The system needs to see more information so that it can be sufficiently accurate to be used in clinical practice and should become more accurate in identifying these viruses as it sees more and more information from patients.

This study will take place at Portsmouth Hospitals University NHS Trust and aims to recruit 1000 patients. To do this, we will recruit both adults and children who either present to the emergency department or are admitted to QAH with a clinical suspicion of a respiratory viral infection. All participants will have a nose and/or throat swab taken as part of their clinical assessment, and we would ask to take a further nasal swab for the purpose of the study. Research sampling will be combined with routine clinical samples where possible to reduce the frequency of testing. We will use most of the information to teach the system how to become more accurate at identifying respiratory viruses. We will keep the remaining information separate and use it to test how accurate the system is. All of the data will be kept securely. Basic information will be collected including age, gender, results of blood tests taken for clinical review, treatment and outcome data. No results from the swabs taken for the purpose of the study will be available to either the participant or the clinical team and the information will have no effect on patient care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

NHS services always come under pressure over the winter period as demand for hospital services increase with the arrival of cold weather and the increase spread of respiratory infections.

As hospitals now look beyond the COVID-19 pandemic, the need to meet future hospital service challenges are important. Changes in habit and measures put in place to control the spread of COVID-19 have affected the transmission of other respiratory viruses. Understanding changes in occurrences of respiratory like illnesses during the winter period could help in understanding future winter pressures for healthcare services.

Since viral and bacterial infection symptoms can be similar, broad spectrum antibiotics are often used as the first line of defence even when the cause of infection is unknown. Antibiotics are not effective against viral infections and only work against bacteria. Antibiotics prevent millions of deaths each year however, inappropriate prescription rates and overuse have led to antibiotic resistance that has created a global health emergency in superbugs resistant to these treatments. There is a need for rapid and sensitive tests to diagnose the cause of infection and ensure patients get the most suitable type of treatment.

THE TECHNOLOGY The hospital is working closely with Pictura Bio, who are developing a rapid pathogen identification technology comprising microscope and a computer which is trained to recognise fluorescent patterns from different viruses. The performance of this AI algorithm is highly dependent on the quality of the samples used to train it. It has the potential to be quicker than current gold standard technology and could be used in a patient facing setting including GP surgeries and Pharmacies.

THE RESEARCH STUDY This is a proof of concept study to determine whether the Pictura Bio system is able to detect and differentiate different viruses from nasopharyngeal swabs/aspirate specimens. The data collected will be used to "train" the algorithms to be able to accurately identify respiratory viruses. The accuracy with which the algorithms estimate the test dataset will be monitored at regular intervals during the training dataset collection period. The Pictura Bio system is still under development, which means that it is still "learning". The system needs to see more information so that it can be sufficiently accurate to be used in clinical practice and should become more accurate in identifying these viruses as it sees more and more information from patients.

This study will take place at Portsmouth Hospitals University NHS Trust and aims to recruit 1000 patients. To do this, we will recruit both adults and children who either present to the emergency department or are admitted to QAH with a clinical suspicion of a respiratory viral infection. All participants will have a nose and/or throat swab taken as part of their clinical assessment, and we would ask to take a further nasal swab for the purpose of the study. Research sampling will be combined with routine clinical samples where possible to reduce the frequency of testing. We will use most of the information to teach the system how to become more accurate at identifying respiratory viruses. We will keep the remaining information separate and use it to test how accurate the system is. All of the data will be kept securely. Basic information will be collected including age, gender, results of blood tests taken for clinical review, treatment and outcome data. No results from the swabs taken for the purpose of the study will be available to either the participant or the clinical team and the information will have no effect on patient care.

SHARING OF FINDINGS Results of the study will be disseminated via paper submissions to relevant journals and conferences. A lay summary of the results will be produced in collaboration with the PHT PRA group. The study team will explore with this group other avenues and formats for the dissemination of the study findings to ensure as wide a public audience as possible, for example through co-produced public talks, articles in community communications and social media.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infections, Respiratory Respiratory Tract Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Covid Positive

Nasopharyngeal Swab

No interventions assigned to this group

Covid Negative

Nasopharyngeal Swab

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide informed, (parental/guardian, where appropriate) consent
* Able to provide nasopharyngeal swab/aspirate specimens.
* A clinical suspicion of a respiratory viral infection with one or more of the following symptoms:
* Coryzal symptoms (runny nose, sneezing and/or nasal congestion)
* New onset of cough
* Sore throat
* Head and/or Muscle aches
* Fever or chills

Exclusion Criteria

* Unable to comply with study procedures or where in the opinion of the investigator, undertaking a nasopharyngeal swab may be detrimental to the individual
* Lacking capacity to consent
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Portsmouth Hospitals NHS Trust

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sharon Glaysher, Dr

Role: PRINCIPAL_INVESTIGATOR

Portsmouth University Hospital NHS Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital

Portsmouth, Hampshire, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yvette Hibberd

Role: CONTACT

023 9228 6000 ext. 5153

Joe Shoebridge

Role: CONTACT

023 9228 6000 ext. 5153

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PHU/2022/64

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Viral Respiratory Infections
NCT06764381 NOT_YET_RECRUITING
Respiferon Project
NCT06017310 UNKNOWN